2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108578
    RuBi-4AP 851956-02-0 98%
    RuBi-4AP, a derivative of 4-aminopyridine (4AP; HY-B0604), is a caged Kv channel blocker. RuBi-4AP contains a photolabile protecting group, allowing its effect to be controlled precisely in both space and time with light. RuBi-4AP can be used for the research of neuronal excitability, synaptic transmission, and signal propagation.
    RuBi-4AP
  • HY-108654
    PSB 0474 917567-60-3 98%
    PSB 0474 (3-phenacyl-UDP) is a selective and potent P2Y6 receptor agonist with an EC50 of 70 nM. PSB 0474 inhibits cell proliferation, increases NO release in astrocytes and microglia cells. PSB 0474 induces astrocytes apoptosis.
    PSB 0474
  • HY-108657
    MRS2279 367909-40-8 98%
    MRS2279 is a selective and high affinity P2Y1 receptor antagonist, with a Ki of 2.5 nM and an IC50 of 51.6 nM. MRS2279 competitively inhibits ADP-promoted platelet aggregation with an apparent affnity (pKB=8.05).
    MRS2279
  • HY-108663
    5-OMe-UDP 1207530-98-0 98%
    5-OMe-UDP (5-methoxyuridine 5'-trihydrogen diphosphate) is a P2Y6 receptor agonist (EC50=0.08 μM). 5-OMe-UDP activates the P2Y6 receptor by binding to it, which triggers signaling pathways within the cell. This activation can lead to an increase in intracellular calcium ion concentration, which in turn regulates cellular function. The methoxy groups of 5-OMe-UDP provide additional activity and selectivity, contributing to the binding of 5-OMe-UDP to the P2Y6 receptor. 5-OMe-UDP can be used to study diseases related to P2Y6 receptor function, such as diabetes, inflammatory bowel disease, Alzheimer's disease, etc.
    5-OMe-UDP
  • HY-108679
    WAY-267464 hydrochloride 1432043-31-6 98%
    WAY-267464 (hydrochloride) is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 (hydrochloride) can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 (hydrochloride) can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder.
    WAY-267464 hydrochloride
  • HY-108920
    4-Chlorokynurenine 153152-32-0 99.94%
    4-Chlorokynurenine is a prodrug of a NMDA receptor antagonist. 4-Chlorokynurenine has orally active and blood-brain permeability that can be used for the research of depression.
    4-Chlorokynurenine
  • HY-108973
    Ifoxetine hemisulfate 98518-48-0 98%
    Ifoxetine is an inhibitor of 5-HT reuptake. Ifoxetine inhibits the uptake of radiolabelled 5-HT into rat brain synaptosomes in vitro or ex vivo.
    Ifoxetine hemisulfate
  • HY-108976
    Raclopride tartrate 98185-20-7 98%
    Raclopride tartrate is a selective dopamine D2/D3 receptor antagonist with potential antipsychotic effects. Raclopride tartrate binds to D2 and D3 receptors with Kis of 1.8 nM and 3.5 nM, respectively.
    Raclopride tartrate
  • HY-108977
    VUF 8430 98021-17-1 98%
    VUF 8430 is a potent and selective histamine H4 receptor agonist with a Ki of 31.6 nM and an EC50 of 50 nM.
    VUF 8430
  • HY-108985
    Trazium esilate 97110-59-3 98%
    Trazium esilate (EGYT-3615) is an antidepressant, which influences the central dopaminergic system. Trazium esilate synergizes amphetamine, potentiates stereotypy and hypermotility. Trazium esilate blocks Apomorphine (HY-12723)-induced hypothermic and the stereotypy, and Bulbocapnine (HY-W436270)-induced cataleptic state. Trazium esilate enhances the effect of Norepinephrine (HY-13715) on isolated vas deferens of the rat.
    Trazium esilate
  • HY-109006
    Ilmetropium iodide 129109-88-2 98%
    Ilmetropium iodide is an anticholinergic agent. Ilmetropium iodide selectively blocks M-cholinergic receptors of bronchial muscle, reduces or prevents bronchoconstrictor response associated with both cholinergic stimulation, as well as the impact of the factors that provoke bronchospasm. Strength and selectivity of ilmetropium iodide action substantially exceeds Atropine sulfate (HY-B1205A) and Ipratropium bromide (HY-B0241).
    Ilmetropium iodide
  • HY-109033
    Fosmetpantotenate 1858268-66-2 98%
    Fosmetpantotenate is a phosphopantothenic acid (PPA) precursor designed to release PPA intracellularly, leading to restoration of CoA levels. Fosmetpantotenate is used to research pantothenate kinase-associated neurodegeneration.
    Fosmetpantotenate
  • HY-109036
    Landipirdine 1000308-25-7 99.80%
    Landipirdine (RO5025181; SYN120) is an orally active 5-HT6 and 5-HT2A receptors antagonist. Landipirdine can be used for the study of Parkinson disease.
    Landipirdine
  • HY-109064
    Loxicodegol 1211231-76-3 98%
    Loxicodegol (Oxycodegol) is a first-in-class, long-acting, orally active, and selective mu-opioid agonist with structural properties that reduce its rate of entry across the blood-brain barrier compared with traditional mu-opioid agonists.
    Loxicodegol
  • HY-109067
    Opiranserin 1441000-45-8 98%
    Opiranserin (VVZ-149), a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin is development as an injectable agent for the treatment of postoperative pain.
    Opiranserin
  • HY-109118
    Masupirdine free base 701205-60-9 98%
    Masupirdine free base (SUVN-502 free base) is a potent, selective, orally bioavailable, and brain penetrant 5-HT6 receptor antagonist (Ki of 2.04 nM for human 5-HT6 receptor). Masupirdine free base (SUVN-502 free base) shows high selectivity over 5-HT2A receptor and other 100 target sites, and has potential for treatment of Alzheimer's disease.
    Masupirdine free base
  • HY-109133
    Pecavaptan 1914998-56-3 98%
    Pecavaptan is an orally active and dual antagonist of V1a/V2 receptor (Ki=0.5 nM and 0.6 nM for human, respectively). Pecavaptan promotes an increase in urine production, which reduces the associated symptoms of water retention and edema.
    Pecavaptan
  • HY-109147
    Imnopitant 290297-57-3 98%
    Imnopitant is a NK1 receptor antagonist (WO2020132716, compound 1) .
    Imnopitant
  • HY-109149
    Lomardexamfetamine 1032291-80-7 98%
    Lomardexamfetamine (KP 106) is an orally active central nervous system stimulant composed of d-amphetamine and a ligand. Lomardexamfetamine can be used for the research of attention-deficit hyperactivity disorder.
    Lomardexamfetamine
  • HY-10933S
    CX516-d10 1286653-21-1 98%
    CX516-d10 is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).
    CX516-d10
Cat. No. Product Name / Synonyms Application Reactivity